Anavex Life Sciences Corp AVXL:NASDAQ

Last Price$17.03NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/03/21
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$16.85 (2)
Ask (Size)$17.05 (38)
Day Low / HighN/A - N/A
Volume928.8 K
 

View Biotechnology IndustryPeer Comparison as of 12/03/2021

 

Anavex Life Sciences Corp ( NASDAQ )

Price: $17.03
Change: -1.01 (5.60%)
Volume: 928.8 K
4:00PM ET 12/03/2021
 
 

Replimune Group Inc ( NASDAQ )

Price: $27.66
Change: -1.32 (4.55%)
Volume: 247.2 K
4:00PM ET 12/03/2021
 
 

Regenxbio Inc ( NASDAQ )

Price: $30.59
Change: -1.05 (3.32%)
Volume: 412.3 K
4:00PM ET 12/03/2021
 
 

FibroGen Inc ( NASDAQ )

Price: $13.51
Change: -0.25 (1.82%)
Volume: 2.2 M
4:00PM ET 12/03/2021
 
 

ImmunoGen Inc ( NASDAQ )

Price: $6.62
Change: -0.54 (7.54%)
Volume: 8.1 M
4:00PM ET 12/03/2021
 

Read more news Recent News

Anavex Life Sciences Posts Wider Loss, Higher Operating Expenses in Fiscal 2021
8:16AM ET 11/24/2021 MT Newswires

Anavex Life Sciences (AVXL) on Wednesday posted a net loss of $0.54 per share in fiscal 2021, compared with a loss of $0.45 per share a year earlier. ...

--BTIG Starts Anavex Life Sciences at Buy with $35 Price Target
10:12AM ET 9/23/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Anavex Life Sciences Says Fragile X Syndrome Treatment Was Effective in Mice in Preclinical Study
1:07PM ET 8/26/2021 MT Newswires

Anavex Life Sciences (AVXL) said Thursday a preclinical study of ANAVEX 2-73, or blarcamesine, showed the experimental treatmnt for symptoms of Fragile X...

Top Premarket Gainers
8:02AM ET 7/29/2021 MT Newswires

LendingClub (LC) shares soared 42% after the company swung to a surprise profit in Q2. Huttig Building Products (HBP) shares surged 18% after the company...

Company Profile

Business DescriptionAnavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY. View company web site for more details
Address630 5th Avenue
New York, New York 10111
Phone+1.844.689.3939
Number of Employees13
Recent SEC Filing11/24/202110-K
Chairman, President, CEO & SecretaryChristopher U. Missling
Chief Operating OfficerStephan Toutain
Principal Financial Officer & TreasurerSandra Boenisch
Chief Medical OfficerWalter E. Kaufmann

Company Highlights

Price Open$18.08
Previous Close$18.04
52 Week Range$4.51 - 31.50
Market Capitalization$1.3 B
Shares Outstanding76.0 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement02/10/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.48
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit MarginN/A
Return on Equity-41.97%

Analyst Ratings as of 11/24/2021

Buy
5
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset